A Phase I, Double-Blind, Randomized, Placebo-Controlled Ascending IV Single-Dose Tolerance and Pharmacokinetic Study of Trodusquemine (MSI-1436) in Obese Type 2 Diabetics

Trial Profile

A Phase I, Double-Blind, Randomized, Placebo-Controlled Ascending IV Single-Dose Tolerance and Pharmacokinetic Study of Trodusquemine (MSI-1436) in Obese Type 2 Diabetics

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Dec 2008

At a glance

  • Drugs Trodusquemine (Primary)
  • Indications Obesity; Type 2 diabetes mellitus
  • Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacokinetics
  • Sponsors Genaera Corporation
  • Most Recent Events

    • 09 Dec 2008 Status changed from recruiting to completed, based on information from ClinicalTrials.gov.
    • 25 Jul 2008 Interim safety and pharmacokinetic data have been reported at the CBI 4th Annual Obesity Drug Development Summit in Arlington, Virginia, USA, according to a Genaera Corporation media release.
    • 17 Jan 2008 Patient dosing has been initiated.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top